<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184938</url>
  </required_header>
  <id_info>
    <org_study_id>OPIRI</org_study_id>
    <nct_id>NCT00184938</nct_id>
  </id_info>
  <brief_title>Opioid Receptors Influence Ischemia-Reperfusion Injury</brief_title>
  <official_title>Opioid Induced Acute Preconditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The most powerful protective mechanism against ischemia-reperfusion injury other than rapid
      reperfusion is ischemic preconditioning. Ischemic preconditioning is defined as the
      development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia
      resulting in a marked reduction in infarct size. This mechanism can be mimicked by several
      pharmacological substances such as adenosine and morphine.

      We, the researchers at Radboud University Nijmegen Medical Centre, have recently developed a
      method in which we can detect ischemia-reperfusion injury in the human forearm by using
      Annexin A5 scintigraphy (Rongen et al). With this method we will determine whether opioid
      receptors are involved in ischemic preconditioning. We expect to find that morphine can mimic
      ischemic preconditioning and that acute ischemic preconditioning can be blocked with the
      opioid receptor antagonist naloxon. This study will increase our knowledge about the
      mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous
      protective mechanism in a clinical setting.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>January 2005</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentual difference in Annexin A5 targetting between the experimental and control arm 1 and 4 hours after intravenous injection</measure>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ischemia-Reperfusion Injury</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naloxone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technetium-TC99m-labeled Annexin A5</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>forearm ischemic exercise</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ten minute forearm ischemia</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers

        Exclusion Criteria:

          -  Exposition to radiation due to imaging techniques in the previous five years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Rongen, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.</citation>
    <PMID>15623546</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 27, 2008</last_update_submitted>
  <last_update_submitted_qc>March 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2008</last_update_posted>
  <keyword>opioids</keyword>
  <keyword>ischemic preconditioning</keyword>
  <keyword>morphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Annexin A5</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

